A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Recruiting · Phase 1, Phase 2 · NCT04973605
Conditions: Relapsed/Refractory Multiple Myeloma
At a glance
- Research payments reported, 2025
- $3.8M
- U.S. investigators named
- 17
- Sites paid
- 21
- Planned or actual enrollment
- 246
About the trial
- Sponsor
- BeOne Medicines
- Tested
- Sonrotoclax (drug), Dexamethasone (drug), Carfilzomib (drug), Daratumumab (drug), Pomalidomide (drug)
- Dates
- Started 2021-09-16; completion 2026-11
- Results posted
- Not yet
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14). The study investigates sonrotoclax alone and in combination with dexamethasone and other agents, including carfilzomib, daratumumab, and pomalidomide.
From ClinicalTrials.gov, last updated 2026-10-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $3.8M in research payments for this study in 2025 (263 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Susan Bal Hematology & Oncology · Birmingham, AL
- Nitya A. Nathwani, M.D. Hematology · Duarte, CA
- Dickran G. Kazandjian, M.D. Hematology & Oncology · Miami, FL
- Jonathan L. Kaufman, M.D. Medical Oncology · Atlanta, GA
- Mohammad Hussain, MD Hematology · Iowa City, IA
- Benjamin Derman Hematology & Oncology · Chicago, IL
- Chukwuemeka C. Uzoka, M.D Internal Medicine · Chicago, IL
- Andrew J. Yee, MD Medical Oncology · Boston, MA
- Michael J. Slade, MD Medical Oncology · Saint Louis, MO
- Harsh Parmar, MD Medical Oncology · Hackensack, NJ
- Malin Hultcrantz, MD PHD Hematology & Oncology · New York, NY
- Ruben Niesvizky, MD Hematology & Oncology · New York, NY
- Elvira R. Umyarova, MD Hematology · Columbus, OH
- Douglas W. Sborov, M.D. Hematology & Oncology · Salt Lake City, UT
- Mary L. Kwok, M.D. Hematology & Oncology · Seattle, WA
- Natalie S. Callander, MD Hematology · Madison, WI
- Binod Dhakal, MD Hematology & Oncology · Milwaukee, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- The Medical College of Wisconsin $678,413
- The Medical College of Wisconsin, Inc. $492,775
- University of Washington Medical Ctr, WA $437,942
- The Board of Regents of the University of Wisconsin System $383,023
- Foedert Hosp Cancer Ctr $343,700
- University of Alabama Hospital, AL $256,941
- Hackensack University Medical Center, NJ $219,132
- City of Hope National Medical Ctr $159,691
- Memorial Sloan Kettering Cancer Center $146,833
- University of Utah Hospital and Clinics, UT $130,325
- Emory University Hospital, GA $121,162
- Washington University $93,231
- Massachusetts General Hospital, MA $62,167
- University of Miami $57,238
- The Ohio State University Dba: Comprehensive Canc $51,357
- Memorial Sloan Kettering Cancer Ctr $49,128
- The University of Chicago $37,136
- Weill Cornell Medical College $35,844
- Dana Farber Mass General Brigham Cancer Care Inc $19,918
- Southern Illinois University School of Medicine $16,939
- University of Illinois Hospital and Clinics, IL $2,975
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.